1. People's Republic of China Stocks

  2. •

    Consumer Cyclical

  3. •

    Restaurants
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd

600721.SS
Xinjiang Bai Hua Cun Pharma Tech Co.,LtdCN flagShanghai Stock Exchange
6.69
CNY
-0.11
- -
2.57BMarket Cap
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd
600721.SS
(Shanghai Stock Exchange)

Recent

price

6.69

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.28
4.5
4.16
4.61
4.46
3.23
2.64
1.05
1.05
0.66
0.22
0.75
0.93
0.97
1.01
1.01
0.68
Revenue per Share
0.25
0.28
0.08
0.01
-0.94
-1.62
0.49
-1.41
-1.69
0.09
-0.82
0.16
-0.09
0.03
0.11
0.11
0.05
Basic EPS, GAAP
-1.69
0.34
0.66
-0.66
0.46
1.37
-0.52
-0.26
0.06
-0.08
-0.07
0.08
0.14
0.12
0.15
0.03
-0.03
Free Cash Flow per Basic Share
0.72
0.49
0.35
0.58
0.45
0.39
0.06
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.43
1.15
1.23
1.22
0.37
-1.33
-0.15
-1.51
-3.2
-3.16
-4.12
-4.13
-4.2
-4.12
-3.97
1.12
1.13
Book Value per Share
3
2.01
2.05
3.06
1.81
0.21
2.04
1.58
1.82
1.93
1.54
1.77
1.71
1.78
1.86
1.95
1.97
Tangible Book Value per Share
163
269
269
268
249
250
282
400
400
400
390
375
376
379
382
384
384
Basic Weighted Avg Shares
697
1,210
1,119
1,235
1,109
809
745
420
419
262
85
281
350
369
386
388
262
Sales/Revenue/Turnover
24.66
22.54
18.22
12.07
-16.48
-33.02
-12.91
16.39
30.82
21.57
-247.46
29.52
8.13
18.62
24.03
20.12
15.46
Operating Margin (%)
78
118
176
204
168
170
105
19
27
30
30
25
26
23
19
19
- -
Depreciation Expense
41
76
20
2
-234
-406
139
-564
-675
34
-320
60
-35
13
41
41
19
Net Income, GAAP
23.77
35.19
43.63
75.47
- -
- -
43.13
- -
- -
19.74
- -
3.7
- -
21.29
- -
7.87
9.11
Effective Tax Rate (%)
5.89
6.24
1.83
0.17
-21.07
-50.2
18.69
-134.47
-161.09
13.12
-378.28
21.26
-9.94
3.51
10.75
10.48
7.41
Profit Margin (%)
-606
-913
-1,352
-1,421
-1,782
-2,261
291
272
332
314
132
214
216
256
274
319
321
Working Capital
935
1,172
740
440
210
76
22
17
12
29
- -
- -
2
1
- -
- -
- -
LT Debt
1,049
1,098
1,104
1,371
997
455
2,298
1,733
919
939
624
686
667
707
759
802
808
Total Equity
5.2
6.17
3.93
1.28
- -
- -
-3.35
- -
- -
4.8
- -
12.16
- -
7.9
- -
9.65
4.56
Return on Invested Capital (%)
1.75
4.68
3.44
1.27
- -
- -
199.05
- -
- -
-2.89
- -
-3.81
- -
-0.83
- -
-7.46
-3.74
Return on Capital (%)
27.43
27.82
6.41
0.64
-111.26
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
20
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
385
385
Market Capitalization
3,641
4,697
3,909

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
565
556
Cash, Cash Equivalents & STI
- -
299
293
Accounts Receivable, Net
- -
125
120
Inventories
- -
30
30
Total Current Liabilities
- -
247
235
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
20
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
32.83%
5.23%
5.7%
Free Cash Flow
-73.86%
-38.84%
-77.69%
Net Income, GAAP
-195.14%
-39.26%
-1.91%
Sales/Revenue/Turnover
11.1%
53.57%
0.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
91
105
94
95
386
2025
97
105
- -
90
388
2026
67
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
- -
- -
- -
0.11
2025
0.05
- -
- -
- -
0.11
2026
0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
DP Poland Plc (DPP.L)
Restaurant Brands New Zealand Limited (RTBRF)
General Assembly Holdings Limited (GASMF)
Ajisen (China) Holdings Limited (0538.HK)
Kaihan Co., Ltd. (3133.T)
Watami Co., Ltd. (7522.T)
Business
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd operates primarily in comprehensive pharmaceutical services, encompassing the development and registration of small molecule chemicals and peptide-based drugs. The company’s core activities span early-stage drug discovery, clinical investigations, biological sample analysis, and medicine testing. Furthermore, it engages in providing active pharmaceutical ingredients, intermediate supplies, and related technology services, alongside its involvement in property leasing. Formed in 1959, the enterprise is headquartered in Urumqi, China.